Overview of medical insurance pricing of pazopanib/pazopanib in 2024

Pazopanib/Pazopanib is a targeted therapy drug that has been strictly approved by the National Medical Products Administration and successfully marketed. This drug is mainly used to treat patients with advanced renal cell carcinoma (RCC). Thanks to the active intervention of the National Medical Insurance Administration, patients who meet specific indications now have the opportunity to enjoy the reimbursement policy of Class B medical insurance.

Currently, the mainstream specifications of pazopanib on the market include200mg and 400mg. The price of its original drugs is roughly around 3,000 yuan, but please note that the actual price may fluctuate slightly depending on geographical location.

As a tyrosine kinase inhibitor (TKI), pazopanib effectively prevents further proliferation of tumor cells and the formation of new blood vessels by disrupting intracellular growth signal transmission, thereby achieving therapeutic purposes. After a series of preclinical evaluations, pazopanib has shown strong anti-angiogenic and anti-tumor capabilities. What's more worth mentioning is that when it is used in combination with chemotherapy drugs, it can produce a one plus one greater than two effect, significantly improving the treatment effect.

Thanks to current health insurance policies and reimbursement mechanisms, those eligible patients can significantly reduce their financial pressure and ensure that more people can receive life-saving treatment. However, it is worth noting that due to differences in the reimbursement ratios of medical insurance in various places, the final costs that patients need to bear will also be different. For those patients who fail to meet the reimbursement standards, although they need to bear all the costs themselves, the medical insurance price still has certain advantages compared with the market price.

In summary, pazopanib occupies a pivotal position in the treatment of renal cell carcinoma. In the future, more patients will be able to benefit from such innovative drugs, thereby achieving better treatment effects and enjoying a higher quality of life.